翰宇药业：拟定增募资不超9.68亿元 用于司美格鲁肽研发等项目

Core Viewpoint - Han Yu Pharmaceutical (300199) announced a plan to issue A-shares to specific investors in 2025, aiming to raise no more than 968 million yuan for various projects [1] Group 1: Fundraising Purpose - The funds will be used for the expansion of peptide drug production lines and green intelligent upgrades [1] - Additional funds will support the construction of peptide fragment production expansion projects [1] - The financing will also facilitate the research and development of Semaglutide [1]